Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections.

Bender AM, Simonetti FR, Kumar MR, Fray EJ, Bruner KM, Timmons AE, Tai KY, Jenike KM, Antar AAR, Liu PT, Ho YC, Raugi DN, Seydi M, Gottlieb GS, Okoye AA, Del Prete GQ, Picker LJ, Mankowski JL, Lifson JD, Siliciano JD, Laird GM, Barouch DH, Clements JE, Siliciano RF.

Cell Host Microbe. 2019 Jul 10;26(1):73-85.e4. doi: 10.1016/j.chom.2019.06.005.

PMID:
31295427
2.

Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size.

Rosenbloom DIS, Bacchetti P, Stone M, Deng X, Bosch RJ, Richman DD, Siliciano JD, Mellors JW, Deeks SG, Ptak RG, Hoh R, Keating SM, Dimapasoc M, Massanella M, Lai J, Sobolewski MD, Kulpa DA, Busch MP; Reservoir Assay Validation and Evaluation Network (RAVEN) Study Group.

PLoS Comput Biol. 2019 Apr 12;15(4):e1006849. doi: 10.1371/journal.pcbi.1006849. eCollection 2019 Apr.

3.

A quantitative approach for measuring the reservoir of latent HIV-1 proviruses.

Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, Fray EJ, Beg SA, Antar AAR, Jenike KM, Bertagnolli LN, Capoferri AA, Kufera JT, Timmons A, Nobles C, Gregg J, Wada N, Ho YC, Zhang H, Margolick JB, Blankson JN, Deeks SG, Bushman FD, Siliciano JD, Laird GM, Siliciano RF.

Nature. 2019 Feb;566(7742):120-125. doi: 10.1038/s41586-019-0898-8. Epub 2019 Jan 30.

4.

The role of CD32 during HIV-1 infection.

Bertagnolli LN, White JA, Simonetti FR, Beg SA, Lai J, Tomescu C, Murray AJ, Antar AAR, Zhang H, Margolick JB, Hoh R, Deeks SG, Tebas P, Montaner LJ, Siliciano RF, Laird GM, Siliciano JD.

Nature. 2018 Sep;561(7723):E17-E19. doi: 10.1038/s41586-018-0494-3. Epub 2018 Sep 19. No abstract available.

5.

Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane.

Wang Z, Gurule EE, Brennan TP, Gerold JM, Kwon KJ, Hosmane NN, Kumar MR, Beg SA, Capoferri AA, Ray SC, Ho YC, Hill AL, Siliciano JD, Siliciano RF.

Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2575-E2584. doi: 10.1073/pnas.1720665115. Epub 2018 Feb 26.

6.

HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.

Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE, Abdel-Mohsen M, Pohlmeyer CW, Fromentin R, Hoh R, Liu AY, McCune JM, Spindler J, Metcalf-Pate K, Hobbs KS, Thanh C, Gibson EA, Kuritzkes DR, Siliciano RF, Price RW, Richman DD, Chomont N, Siliciano JD, Mellors JW, Yukl SA, Blankson JN, Liegler T, Deeks SG.

PLoS Med. 2017 Nov 7;14(11):e1002417. doi: 10.1371/journal.pmed.1002417. eCollection 2017 Nov.

7.

Assays to Measure Latency, Reservoirs, and Reactivation.

Siliciano JD, Siliciano RF.

Curr Top Microbiol Immunol. 2018;417:23-41. doi: 10.1007/82_2017_75. Review.

PMID:
29071475
8.

Transcriptional Reprogramming during Effector-to-Memory Transition Renders CD4+ T Cells Permissive for Latent HIV-1 Infection.

Shan L, Deng K, Gao H, Xing S, Capoferri AA, Durand CM, Rabi SA, Laird GM, Kim M, Hosmane NN, Yang HC, Zhang H, Margolick JB, Li L, Cai W, Ke R, Flavell RA, Siliciano JD, Siliciano RF.

Immunity. 2017 Oct 17;47(4):766-775.e3. doi: 10.1016/j.immuni.2017.09.014.

9.

Reduced Frequency of Cells Latently Infected With Replication-Competent Human Immunodeficiency Virus-1 in Virally Suppressed Individuals Living in Rakai, Uganda.

Prodger JL, Lai J, Reynolds SJ, Keruly JC, Moore RD, Kasule J, Kityamuweesi T, Buule P, Serwadda D, Nason M, Capoferri AA, Porcella SF, Siliciano RF, Redd AD, Siliciano JD, Quinn TC.

Clin Infect Dis. 2017 Oct 15;65(8):1308-1315. doi: 10.1093/cid/cix478.

10.

Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics.

Hosmane NN, Kwon KJ, Bruner KM, Capoferri AA, Beg S, Rosenbloom DI, Keele BF, Ho YC, Siliciano JD, Siliciano RF.

J Exp Med. 2017 Apr 3;214(4):959-972. doi: 10.1084/jem.20170193. Epub 2017 Mar 24.

11.

Insufficient Evidence for Rare Activation of Latent HIV in the Absence of Reservoir-Reducing Interventions.

Hill AL, Rosenbloom DI, Siliciano JD, Siliciano RF.

PLoS Pathog. 2016 Aug 25;12(8):e1005679. doi: 10.1371/journal.ppat.1005679. eCollection 2016 Aug. No abstract available.

12.

Defective proviruses rapidly accumulate during acute HIV-1 infection.

Bruner KM, Murray AJ, Pollack RA, Soliman MG, Laskey SB, Capoferri AA, Lai J, Strain MC, Lada SM, Hoh R, Ho YC, Richman DD, Deeks SG, Siliciano JD, Siliciano RF.

Nat Med. 2016 Sep;22(9):1043-9. doi: 10.1038/nm.4156. Epub 2016 Aug 8.

13.

Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy.

Lee SA, Bacchetti P, Chomont N, Fromentin R, Lewin SR, O'Doherty U, Palmer S, Richman DD, Siliciano JD, Yukl SA, Deeks SG, Burbelo PD.

PLoS One. 2016 Aug 2;11(8):e0160192. doi: 10.1371/journal.pone.0160192. eCollection 2016.

14.

Recent developments in the effort to cure HIV infection: going beyond N = 1.

Siliciano JD, Siliciano RF.

J Clin Invest. 2016 Feb;126(2):409-14. doi: 10.1172/JCI86047. Epub 2016 Feb 1. Review.

15.

Measuring the Frequency of Latent HIV-1 in Resting CD4⁺ T Cells Using a Limiting Dilution Coculture Assay.

Laird GM, Rosenbloom DI, Lai J, Siliciano RF, Siliciano JD.

Methods Mol Biol. 2016;1354:239-53. doi: 10.1007/978-1-4939-3046-3_16.

PMID:
26714716
16.

Reply: To PMID 25117799.

Siliciano JD, Siliciano RF.

J Allergy Clin Immunol. 2015 Jul;136(1):214. doi: 10.1016/j.jaci.2015.03.044. Epub 2015 Jun 3. No abstract available.

PMID:
25979523
17.

Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.

Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, Durand CM, Siliciano JD, Siliciano RF.

J Clin Invest. 2015 May;125(5):1901-12. doi: 10.1172/JCI80142. Epub 2015 Mar 30.

18.

HIV-1 integration landscape during latent and active infection.

Cohn LB, Silva IT, Oliveira TY, Rosales RA, Parrish EH, Learn GH, Hahn BH, Czartoski JL, McElrath MJ, Lehmann C, Klein F, Caskey M, Walker BD, Siliciano JD, Siliciano RF, Jankovic M, Nussenzweig MC.

Cell. 2015 Jan 29;160(3):420-32. doi: 10.1016/j.cell.2015.01.020.

19.

Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations.

Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, Lai J, McHugh HL, Hao H, Zhang H, Margolick JB, Gurer C, Murphy AJ, Valenzuela DM, Yancopoulos GD, Deeks SG, Strowig T, Kumar P, Siliciano JD, Salzberg SL, Flavell RA, Shan L, Siliciano RF.

Nature. 2015 Jan 15;517(7534):381-5. doi: 10.1038/nature14053. Epub 2015 Jan 7.

20.
21.

A primary CD4(+) T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence.

Kim M, Hosmane NN, Bullen CK, Capoferri A, Yang HC, Siliciano JD, Siliciano RF.

Nat Protoc. 2014 Dec;9(12):2755-70. doi: 10.1038/nprot.2014.188. Epub 2014 Nov 6.

22.

CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells.

Cockerham LR, Siliciano JD, Sinclair E, O'Doherty U, Palmer S, Yukl SA, Strain MC, Chomont N, Hecht FM, Siliciano RF, Richman DD, Deeks SG.

PLoS One. 2014 Oct 23;9(10):e110731. doi: 10.1371/journal.pone.0110731. eCollection 2014.

23.

Finding a cure for human immunodeficiency virus-1 infection.

Blankson JN, Siliciano JD, Siliciano RF.

Infect Dis Clin North Am. 2014 Dec;28(4):633-50. doi: 10.1016/j.idc.2014.08.007. Epub 2014 Sep 30. Review.

24.

AIDS/HIV. Rekindled HIV infection.

Siliciano JD, Siliciano RF.

Science. 2014 Aug 29;345(6200):1005-6. doi: 10.1126/science.1259452. No abstract available.

PMID:
25170139
25.

Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1.

Siliciano JD, Siliciano RF.

J Allergy Clin Immunol. 2014 Jul;134(1):12-9. doi: 10.1016/j.jaci.2014.05.026. Epub 2014 Jun 26. Review.

PMID:
25117799
26.

New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.

Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF.

Nat Med. 2014 Apr;20(4):425-9. doi: 10.1038/nm.3489. Epub 2014 Mar 23.

27.

A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy.

Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, Emad F, Buckheit R 3rd, McCance-Katz EF, Lai J, Kennedy M, Chander G, Siliciano RF, Siliciano JD, Deeks SG.

Clin Infect Dis. 2014 Mar;58(6):883-90. doi: 10.1093/cid/cit813. Epub 2013 Dec 12.

28.

Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure.

Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF.

Cell. 2013 Oct 24;155(3):540-51. doi: 10.1016/j.cell.2013.09.020. Epub 2013 Oct 24.

29.

Recent trends in HIV-1 drug resistance.

Siliciano JD, Siliciano RF.

Curr Opin Virol. 2013 Oct;3(5):487-94. doi: 10.1016/j.coviro.2013.08.007. Epub 2013 Sep 7. Review.

30.

Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay.

Laird GM, Eisele EE, Rabi SA, Lai J, Chioma S, Blankson JN, Siliciano JD, Siliciano RF.

PLoS Pathog. 2013;9(5):e1003398. doi: 10.1371/journal.ppat.1003398. Epub 2013 May 30.

31.

HIV-1 eradication strategies: design and assessment.

Siliciano JD, Siliciano RF.

Curr Opin HIV AIDS. 2013 Jul;8(4):318-25. doi: 10.1097/COH.0b013e328361eaca. Review.

32.

Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies.

Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, Bosch RJ, Lai J, Chioma S, Emad F, Abdel-Mohsen M, Hoh R, Hecht F, Hunt P, Somsouk M, Wong J, Johnston R, Siliciano RF, Richman DD, O'Doherty U, Palmer S, Deeks SG, Siliciano JD.

PLoS Pathog. 2013 Feb;9(2):e1003174. doi: 10.1371/journal.ppat.1003174. Epub 2013 Feb 14.

33.

Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173.

Gandhi RT, Bosch RJ, Aga E, Bedison MA, Bastow B, Schmitz JL, Siliciano JD, Siliciano RF, Eron JJ, Mellors JW; ACTG A5173 team.

Antivir Ther. 2013;18(4):607-13. doi: 10.3851/IMP2543. Epub 2013 Feb 15.

34.

HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy.

Durand CM, Ghiaur G, Siliciano JD, Rabi SA, Eisele EE, Salgado M, Shan L, Lai JF, Zhang H, Margolick J, Jones RJ, Gallant JE, Ambinder RF, Siliciano RF.

J Infect Dis. 2012 Mar 15;205(6):1014-8. doi: 10.1093/infdis/jir884. Epub 2012 Jan 24.

35.

Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.

Xing S, Bullen CK, Shroff NS, Shan L, Yang HC, Manucci JL, Bhat S, Zhang H, Margolick JB, Quinn TC, Margolis DM, Siliciano JD, Siliciano RF.

J Virol. 2011 Jun;85(12):6060-4. doi: 10.1128/JVI.02033-10. Epub 2011 Apr 6.

36.

Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model.

Shan L, Yang HC, Rabi SA, Bravo HC, Shroff NS, Irizarry RA, Zhang H, Margolick JB, Siliciano JD, Siliciano RF.

J Virol. 2011 Jun;85(11):5384-93. doi: 10.1128/JVI.02536-10. Epub 2011 Mar 23.

37.

Consistent inhibition of HIV-1 replication in CD4+ T cells by acyclovir without detection of human herpesviruses.

McMahon MA, Parsons TL, Shen L, Siliciano JD, Siliciano RF.

J Virol. 2011 May;85(9):4618-22. doi: 10.1128/JVI.02423-10. Epub 2011 Feb 16.

38.

Biomarkers of HIV replication.

Siliciano JD, Siliciano RF.

Curr Opin HIV AIDS. 2010 Nov;5(6):491-7. doi: 10.1097/COH.0b013e32833f206f. Review.

PMID:
20978392
39.

Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs.

McMahon MA, Siliciano JD, Kohli RM, Siliciano RF.

AIDS. 2010 Jan 16;24(2):319-23. doi: 10.1097/QAD.0b013e32833424e5.

PMID:
20009920
40.

No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy.

Gandhi RT, Bosch RJ, Aga E, Albrecht M, Demeter LM, Dykes C, Bastow B, Para M, Lai J, Siliciano RF, Siliciano JD, Eron JJ; AIDS Clinical Trials Group A5173 Team.

J Infect Dis. 2010 Jan 15;201(2):293-6. doi: 10.1086/649569.

41.

Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy.

Brennan TP, Woods JO, Sedaghat AR, Siliciano JD, Siliciano RF, Wilke CO.

J Virol. 2009 Sep;83(17):8470-81. doi: 10.1128/JVI.02568-08. Epub 2009 Jun 17.

42.

Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1.

Wind-Rotolo M, Durand C, Cranmer L, Reid A, Martinson N, Doherty M, Jilek BL, Kagaayi J, Kizza A, Pillay V, Laeyendecker O, Reynolds SJ, Eshleman SH, Lau B, Ray SC, Siliciano JD, Quinn TC, Siliciano RF.

J Infect Dis. 2009 May 1;199(9):1301-9. doi: 10.1086/597759.

43.

The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation.

McMahon MA, Siliciano JD, Lai J, Liu JO, Stivers JT, Siliciano RF, Kohli RM.

J Biol Chem. 2008 Nov 14;283(46):31289-93. doi: 10.1074/jbc.C800188200. Epub 2008 Sep 24.

44.

Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough.

Han Y, Lin YB, An W, Xu J, Yang HC, O'Connell K, Dordai D, Boeke JD, Siliciano JD, Siliciano RF.

Cell Host Microbe. 2008 Aug 14;4(2):134-46. doi: 10.1016/j.chom.2008.06.008.

45.

Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors.

Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN.

J Virol. 2008 Mar;82(6):3125-30. Epub 2007 Dec 12.

46.

Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART.

Sedaghat AR, Siliciano JD, Brennan TP, Wilke CO, Siliciano RF.

PLoS Pathog. 2007 Aug 31;3(8):e122.

47.

Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.

Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, Margolick JB, Gallant JE, Cofrancesco J Jr, Moore RD, Gange SJ, Siliciano RF.

J Infect Dis. 2007 Mar 15;195(6):833-6. Epub 2007 Jan 30.

PMID:
17299713
48.

Experimental approaches to the study of HIV-1 latency.

Han Y, Wind-Rotolo M, Yang HC, Siliciano JD, Siliciano RF.

Nat Rev Microbiol. 2007 Feb;5(2):95-106. Review.

PMID:
17224919
49.

Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors.

Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, Lai J, Gandhi SK, Siliciano JD, Williams TM, Siliciano RF.

J Virol. 2007 Mar;81(5):2508-18. Epub 2006 Dec 6.

50.

Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells.

Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, Wind-Rotolo M, Haggerty CM, Kamireddi AR, Liu Y, Lee J, Persaud D, Gallant JE, Cofrancesco J Jr, Quinn TC, Wilke CO, Ray SC, Siliciano JD, Nettles RE, Siliciano RF.

J Virol. 2006 Jul;80(13):6441-57.

Supplemental Content

Loading ...
Support Center